...be presented in Madrid at the October meeting of the European Society for Impotence Research. Senetek plc...

...Mill Creek Botanicals Age Defiant Skin Preservation System by SNTKY's Carme Cosmeceutical Sciences business unit. Senetek PLC...

...disposition of one or more corporate assets, a potential merger and/or a strategic business combination. Senetek's...
...Solutions Holdings plc (LSE:PLE, London, U.K.) in the North America to treat erectile dysfunction (ED). Senetek...
...30, Senetek had $13 million in cash and a six-month operating loss of $2.5 million. Senetek plc...

...The academy granted Senetek exclusive, worldwide rights to a technology that inhibits an undisclosed cancer target...
...undisclosed cancer target using RNA interference (RNAi). The academy is eligible for royalties. In 2006, Senetek...
...academy to another RNAi cancer candidate and three dermatology compounds (see BioCentury, Nov. 13, 2006). Senetek plc...

...distribute Senetek’s Invicorp vasoactive intestinal polypeptide (VIP)/phentolamine injection in Europe to treat erectile dysfunction (ED). Senetek...
...into administration last month. The product is marketed in Denmark, New Zealand and the U.K. Senetek...
...North America. (see BioCentury, June 28, 2004, & June 30). Ardana plc (LSE:ARA), Edinburgh, U.K. Senetek plc...

...Switzerland); to Striant SR from Columbia Laboratories Inc. (NASDAQ:CBRX; Livingston, N.J.); and to Invicorp from Senetek plc...

...SNTKY began a pilot trial in 24 patients. Senetek plc (SNTKY), Napa, Calif. Product: Pyratine 6...

...and the U.K. Ardana plc (LSE:ARA), Edinburgh, U.K. Plethora Solutions Holdings plc (LSE:PLE), London, U.K. Senetek plc...